- Ixico
- 17 July 2025 09:59:06
Source: Sharecast
The AIM-traded neuroscience imaging and biomarker analytics specialist attributed the performance to continued progress under its ‘Innovate Lead Scale’ strategy.
It said the stronger-than-expected performance marked a return to growth and provided momentum heading into 2026, where further revenue expansion was anticipated.
The company said it expected that trajectory to support its path toward medium-term profitability.
It said its growth was supported by increased investment in 2025, aimed at expanding scientific innovation and broadening commercial and geographic reach in neurological and adjacent therapeutic areas.
Ixico said it expected to report cash of at least £3m at the financial year-end.
“The Innovate Lead Scale strategy outlined during our capital raise has begun to deliver results,” said chief executive Bram Goorden.
“The positive momentum is a result of a team approach, executing with discipline to grow revenues, expand market share and diversify the neurological therapeutic areas we operate in.”
Goorden said that in addition, the company was “rapidly advancing” its technology platform offering with new differentiated biomarker analytics products and applications fit for scale.
“This activity strengthens my belief that we will continue to build upon this year's commercial success and the progress we are making towards profitability in the medium term.”
Final results for the year were expected to be published in December.
At 0934 BST, shares in Ixico were up 15.38% at 11.25p.
Reporting by Josh White for Sharecast.com.